Gynaecological sarcomas

Current Opinion in Oncology

Volumn 19, Issue 5, 2007, Pages 492-496

  Sleijfer, Stefan ^a   Seynaeve, Caroline ^a   Verweij, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Gynaecological sarcomas; Patient management; Subtypes

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; HYDROXYUREA; IFOSFAMIDE; IMATINIB; PACLITAXEL; TAMOXIFEN; TEMOZOLOMIDE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; EMBRYONAL RHABDOMYOSARCOMA; ENDOMETRIUM SARCOMA; HUMAN; HYSTERECTOMY; MIXED MULLERIAN TUMOR; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; SURVIVAL RATE; SURVIVAL TIME; UTERUS SARCOMA;

FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; SARCOMA;

EID: 34548388886     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282748eaa     Document Type: Review

References (30)

1. Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 1986; 76:399-402.
2. Lam MM, Corless CL, Goldblum JR, et al. Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall. Int J Gynecol Pathol 2006; 25:288-292.
3. McCluggage WG. Malignant biphasic uterine tumors: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 2002; 55:321-325.
4. McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology 2001; 39:273-278.
5. Skubitz KM, Skubitz APN. Differential gene expression in leiomyosarcoma. Cancer 2003; 98:1029-1038.
6. Giuntoli RL, Bristow RE. Uterine leiomyosarcoma: present management. Curr Opin Oncol 2004; 16:324-327.
7. Norris HJ, Taylor HB. Mesenchymal tumors of the uterus. A clinical and pathological study of 53 endometrial stromal tumors. Cancer 1966; 19:755-766.
8. Dusenbery KE, Potish RA, Argenta PA, Judson PL. On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am J Clin Oncol 2005; 28:295-300.
9. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997; 350:1647-1654.
10. Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecological Oncology Group Study. J Clin Oncol 1985; 3:1240-1245.
11. Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist 2005; 10:833-841.
12. Sutton GP, Blessing JA, Barrett RJ, et al. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecological Oncology Group study. Am J Obstet Gynecol 1992; 166:556-559.
13. Sutton G, Blessing JA, Park R, et al. Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecological Oncology Group. Obstet Gynecol 1996; 87:747-750.
14. Bramwell VHC, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adults with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2001; 4:CD003293.
15. Omura GA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983; 52:626-632.
16. Muss HB, Bundy B, DiSaia PJ, et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecological Oncology Group). Cancer 1985; 55:1648-1653.
17. Kanjeekal S, Chambers A, Fung MFK, Verma S. Systemic therapy for advanced uterine sarcoma: a systemic review of the literature. Gynecol Oncol 2005; 97:624-637.
18. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20:2824-2831.
19. Maki RG, Hensley ML, Wathen JK, et al. A SARC multicenter phase III study of gemcitabine vs. gemcitabine and docetaxel in patients with metastatic soft tissue sarcomas. J Clin Oncol 2006; 24 (18S):9514.
20. Reich O, Regauer S, Urdl W, et al. Expression of estrogen and progesterone receptors in low-grade endometrial stromal sarcomas. Br J Cancer 2000; 82:1030-1034.
21. Reich O, Regauer S. Aromatase expression in low-grade endometrial stromal sarcomas: a immunohistochemical study. Mod Pathol 2004; 17:104-108.
22. Wickerham DL, Fisher B, Wolmark N, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002; 20:2758-2760.
23. Pink D, Linder T, Mrozek A, et al. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol 2006; 101:464-469. A retrospective series and review on hormonal treatment for low-grade endometrial stromal sarcomas.
24. Maluf FC, Sabatini P, Schwartz L, et al. Endometrial stromal sarcoma: objective response to letrozole. Gynecol Oncol 2001; 82:384-388.
25. Sleijfer S, Seynaeve C, Wiemer E, Verweij J. Practical aspects of managing gastrointestinal stromal tumors. Clin Colorectal Cancer 2006; 6 (Suppl 1):S18-S23.
26. Rushing RS, Shajahan S, Chendil D, et al. Uterine sarcoma express KIT but lack mutation(s) in exon 11 or 17 in c-kit. Gynecol Oncol 2003; 91:9-14.
27. Bodner-Adler B, Bodner K, Kimberger O, et al. MMP-1 and MMP-2 expression in uterine leiomyosarcoma and correlation with different clinicopathological parameters. J Soc Gynecol Invest 2003; 10:443-446.
28. Silvestris N, Parra HS, Angelini F, et al. Lack of response to imatinib mesylate as second-line therapy in a patient with c-kit positive metastatic soft tissue leiomyosarcoma. Tumori 2005; 91:103.
29. Zhang L, Hannay JA, Liu J, et al. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. Cancer Res 2006; 66:8770-8778.
30. Willett CG, Boucher Y, Di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-147.